Threshold Pharmaceuticals Announces TH-302 Data to Be Presented at ASH
November 07 2013 - 9:00AM
Marketwired
Threshold Pharmaceuticals Announces TH-302 Data to Be Presented at
ASH
SOUTH SAN FRANCISCO, CA--(Marketwired - Nov 7, 2013) - Threshold
Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that clinical
data on its investigational hypoxia-targeted drug, TH-302, will be
presented at the 55th Annual Meeting of the American Society of
Hematology (ASH), December 7 - 10, 2013, in New Orleans, LA. The
presentations will report early data from two ongoing clinical
trials, one evaluating TH-302 as single-agent monotherapy in
patients with advanced leukemias (Abstract #3920), and another
evaluating TH-302 with low-dose dexamethasone in patients with
relapsed/refractory multiple myeloma (Abstract #1948).
Abstract Details
Abstract #1948: Phase 1 Study of TH-302, an Investigational
Hypoxia-Targeted Drug, and Dexamethasone in Patients with
Relapsed/Refractory Multiple Myeloma; 5:30 PM - 7:30 PM Central
Time on Saturday, December 7, 2013, in Hall G.
Abstract #3920: A Phase 1 Study of TH-302, an Investigational
Hypoxia-Targeted Drug, In Patients With Advanced Leukemias; 6:00 PM
- 8:00 PM Central Time on Monday, December 9, 2013, in Hall E.
Abstracts are now available on the ASH website at
www.hematology.org.
About TH-302
TH-302 is an investigational hypoxia-targeted drug that is
designed to be activated under tumor hypoxic conditions, a hallmark
of many cancers. Areas of low oxygen levels (hypoxia) in solid
tumors are due to insufficient blood supply as a result of aberrant
vasculature. Similarly, the bone marrow of patients with
hematological malignancies has also been shown, in some cases, to
be severely hypoxic.
TH-302 is currently under evaluation in two Phase 3 trials: one
in combination with doxorubicin versus doxorubicin alone in
patients with soft tissue sarcoma, and the other in combination
with gemcitabine versus gemcitabine and placebo in patients with
advanced pancreatic cancer (MAESTRO). Both Phase 3 trials are being
conducted under Special Protocol Agreements with the U.S. Food and
Drug Administration (FDA). The FDA and the European Commission have
granted TH-302 Orphan Drug Designation for the treatment of soft
tissue sarcoma and pancreatic cancer. TH-302 is also being
investigated in hematological malignancies and in combination with
other therapies in a variety of solid tumors.
Threshold has a global license and co-development agreement for
TH-302 with Merck KGaA, Darmstadt, Germany, which includes an
option for Threshold to co-commercialize in the U.S.
About Threshold Pharmaceuticals
Threshold Pharmaceuticals, Inc. is a biotechnology company
focused on the discovery and development of drugs targeting Tumor
Hypoxia, the low oxygen condition found in microenvironments of
most solid tumors as well as the bone marrows of some hematologic
malignancies. This approach offers broad potential to treat a
variety of cancers. By selectively targeting tumor cells, we
are building a pipeline of drugs that hold promise to be more
effective and less toxic to healthy tissues than conventional
anticancer drugs. For additional information, please visit our
website (www.thresholdpharm.com).
Forward-Looking Statements
Except for statements of historical fact, the statements in this
press release are forward-looking statements, including statements
regarding the potential use of TH-302 to treat patients with
advanced leukemias or multiple myeloma, other clinical trials of
TH-302 and the therapeutic uses and benefits of TH-302. These
statements involve risks and uncertainties that can cause actual
results to differ materially from those in such forward-looking
statements. Potential risks and uncertainties include, but are not
limited to, Threshold's ability to enroll or complete its
anticipated clinical trials, the time and expense required to
conduct such clinical trials and analyze data, issues arising in
the regulatory or manufacturing process and the results of such
clinical trials (including product safety issues and efficacy
results). Further information regarding these and other risks is
included under the heading "Risk Factors" in Threshold's Quarterly
Report on Form 10-Q, which has been filed with the Securities and
Exchange Commission on November 4, 2013 and is available from
the SEC's website (www.sec.gov) and on our website
(www.thresholdpharm.com) under the heading "Investors." We
undertake no duty to update any forward-looking statement made in
this news release.
Contact Laura Hansen, Ph.D. Senior Director, Corporate
Communications Threshold Pharmaceuticals Phone: 650-474-8206
E-mail: lhansen@thresholdpharm.com
Molecular Templates (NASDAQ:MTEM)
Historical Stock Chart
From Apr 2024 to May 2024
Molecular Templates (NASDAQ:MTEM)
Historical Stock Chart
From May 2023 to May 2024